Funding Disclosures in 2024 NRAS would like to thank the following companies for supporting the work of NRAS during 2024 and acknowledge financial payment of any consultancy work provided by NRAS to the work undertaken by industry partners. Company NameProject Name/Reason for FundingMonthAmountBeneficiaryTotal 2024 Funding (ex VAT)AbbVie LtdNRAS invited speaker at ‘ARENA’ nurse training eventMay£438.75AbbVie Funding to facilitate dubbing of NRAS SMILE-RA (e-learning platform) exercise modules into South Asian languagesJuly£9,875NRAS £10,313.75 Alfasigma UK LimitedTransfer of ‘We RA Priority’ campaign video content – gift in kind only, value of content gifted listed in ‘amount’.N/A£111,000NRAS Corporate MembershipAugust£12,600NRAS £12,600Amgen LimitedCorporate MembershipJuly£12,000NRAS £12,000AnaptysBio Inc.Corporate MembershipMay£12,600NRAS £12,600 Biogen Idec LimitedCorporate MembershipSeptember£12,600NRAS £12,600Boehringer Ingelheim LimitedNRAS promotion & support on ILD awareness surveyMarch£1,000Boehringer Ingelheim NRAS invited speaker at ‘ILD Academy’ health professional training eventSeptember£1,560Boehringer Ingelheim NRAS support of ‘Real World Data’ project (milestone 1)November£1,560Boehringer Ingelheim £4,120Eli Lilly and Company LimitedCorporate MembershipJanuary£12,000NRAS £12,000Inmedix Inc.‘Stress Matters’ report print & shipping costs to the USAApril£3,315Inmedix £3,315Johnson & Johnson2025 funding for Information & Support services, Right Start and PublicationsDecember£10,000NRAS £10,000Medac Pharma LLPCorporate MembershipJanuary£12,000NRAS Project collaboration on injectable treatments and South Asian resources during 2023 – 2024May£7,980Co-beneficiaries £19,980Sandoz LimitedNRAS attendance at ‘Homecare Hackathon’ eventJanuary£472Sandoz £472UCB Pharma LtdCorporate MembershipMarch£12,000NRAS NRAS attendance at ‘RA Advisory Board’November£600UCB £12,600 Total funding received from the pharmaceutical industry in 2024: £122,600.75